314 results on '"Guedj, E."'
Search Results
2. Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [ 18 F]FDG-PET study.
- Author
-
Horowitz T, Dudouet P, Campion JY, Kaphan E, Radulesco T, Gonzalez S, Cammilleri S, Ménard A, and Guedj E
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Follow-Up Studies, Retrospective Studies, Radiopharmaceuticals pharmacokinetics, COVID-19 diagnostic imaging, COVID-19 complications, COVID-19 metabolism, Fluorodeoxyglucose F18, Brain diagnostic imaging, Brain metabolism, Positron-Emission Tomography
- Abstract
Purpose: A hypometabolic profile involving the limbic areas, brainstem and cerebellum has been identified in long COVID patients using [
18 F]fluorodeoxyglucose (FDG)-PET. This study was conducted to evaluate possible recovery of brain metabolism during the follow-up of patients with prolonged symptoms., Methods: Fifty-six adults with long COVID who underwent two brain [18 F]FDG-PET scans in our department between May 2020 and October 2022 were retrospectively analysed, and compared to 51 healthy subjects. On average, PET1 was performed 7 months (range 3-17) after acute COVID-19 infection, and PET2 was performed 16 months (range 8-32) after acute infection, because of persistent severe or disabling symptoms, without significant clinical recovery. Whole-brain voxel-based analysis compared PET1 and PET2 from long COVID patients to scans from healthy subjects (p-voxel < 0.001 uncorrected, p-cluster < 0.05 FWE-corrected) and PET1 to PET2 (with the same threshold, and secondarily with a less constrained threshold of p-voxel < 0.005 uncorrected, p-cluster < 0.05 uncorrected). Additionally, a region-of-interest (ROI) semiquantitative anatomical approach was performed for the same comparisons (p < 0.05, corrected)., Results: PET1 and PET2 revealed voxel-based hypometabolisms consistent with the previously reported profile in the literature. This between-group analysis comparing PET1 and PET2 showed minor improvements in the pons and cerebellum (8.4 and 5.2%, respectively, only significant under the less constrained uncorrected p-threshold); for the pons, this improvement was correlated with the PET1-PET2 interval (r = 0.21, p < 0.05). Of the 14,068 hypometabolic voxels identified on PET1, 6,503 were also hypometabolic on PET2 (46%). Of the 7,732 hypometabolic voxels identified on PET2, 6,094 were also hypometabolic on PET1 (78%). The anatomical ROI analysis confirmed the brain hypometabolism involving limbic region, the pons and cerebellum at PET1 and PET2, without significant changes between PET1 and PET2., Conclusion: Subjects with persistent symptoms of long COVID exhibit durable deficits in brain metabolism, without progressive worsening., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
3. White matter changes after Gamma Knife Capsulotomy in patients with intractable obsessive-compulsive disorder.
- Author
-
Spatola G, Triebkorn P, Richieri R, Baunez C, Farisse J, Cretol A, Guedj E, Jirsa V, and Regis J
- Abstract
Background: Anterior capsulotomy is one of the therapeutic options for refractory obsessive-compulsive disorder (OCD). Safety and efficacy of Gamma Knife Capsulotomy (GKC) have been demonstrated in the past., Objective: To characterize changes induced by GKC using a fixel-based analysis (FBA) and possible predictors of efficacy., Methods: Patients with OCD refractory to other therapies underwent bilateral GKC with 120 Gy as a maximum dose on the anterior limb of the internal capsule (ALIC). The clinical outcome was percent reduction in Yale- Brown Obsessive-Compulsive Scale (Y-BOCS). White Matter changes were analyzed using fixel-based analysis (FBA) for fibre density (FD), fibre-bundle cross-section (FC) and the combination of the two (FDC)., Results: Seven patients underwent GKC. Median follow-up was 13 months (range 12-58 months). Mean (±SD) decrease in Y-BOCS score at last follow-up was 61 % ± 35 % with five patients considered as responders. FBA showed a symmetric FD reduction in the ALIC with extension to the anterior fronto-thalamic radiation; a reduction of FC along the superior longitudinal fasciculus (SLF) in both hemispheres with a predominance in the left one. Reductions in FDC were detected predominantly in the right hemisphere, with a similar pattern to FD reductions and associated with a positive correlation (p < 0.05) between Y-BOCS reduction and fibres passing in the ventral part., Conclusions: GKC is safe and efficient in reducing OCD severity in selected patients. Changes induced in white matter by GKC extend over the ALIC. Reduction of fibres passing the ventral part of the right sided ALIC correlates with better results., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Jirsa Viktor reports financial support was provided by 10.13039/100007586Aix-Marseille University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
4. Correction to: EANM perspectives for CZT SPECT in brain applications.
- Author
-
Verger A, Cecchin D, Guedj E, Albert NL, Brendel M, Fraioli F, Tolboom N, Traub-Weidinger T, Yakushev I, Van Weehaeghe D, Fernandez PA, Garibotto V, and Imbert L
- Published
- 2024
- Full Text
- View/download PDF
5. Molecular Imaging in CANVAS: A Contribution for Differential Diagnosis?
- Author
-
Horowitz T, Guedj E, Eusebio A, Fluchère F, Azulay JP, Delmont E, and Grimaldi S
- Subjects
- Humans, Male, Diagnosis, Differential, Middle Aged, Female, Aged, Molecular Imaging methods, Multiple System Atrophy diagnostic imaging, Multiple System Atrophy metabolism, Multiple System Atrophy diagnosis, Positron-Emission Tomography methods, Fluorodeoxyglucose F18, Brain diagnostic imaging, Brain metabolism, Dopamine Plasma Membrane Transport Proteins metabolism, Machado-Joseph Disease diagnostic imaging, Machado-Joseph Disease diagnosis, Machado-Joseph Disease metabolism, 3-Iodobenzylguanidine, Tomography, Emission-Computed, Single-Photon methods
- Abstract
Background: Phenotypes of CANVAS are increasingly diversified, including bradykinesia and dysautonomia, so that its primary differential diagnoses are multiple system atrophy-cerebellar type (MSA-c), and spinocerebellar ataxia type 3 (SCA3). This case series aims to highlight key molecular imaging findings in CANVAS., Cases: We report a case series of six patients with CANVAS who underwent nuclear medicine examinations in our center and 13 patients from the literature. These include
18 F-FDG brain positron emission tomography (PET), single photon emission computed tomography (SPECT) of dopamine transporter (DaT) activity, and123 I-MIBG cardiac scintigraphy of noradrenergic transmission., Conclusions: In CANVAS,18 F-FDG brain PET mainly shows cerebellar hypometabolism, with preserved brainstem and striatum metabolism, contrasting with SCA3 and MSA-c. Dopaminergic denervation on scintigraphy seems to be associated with clinical parkinsonism, ranging from normal to severely impaired DaT SPECT. Additionally,123 I-MIBG cardiac scintigraphy might show denervation in CANVAS, similar to SCA3, but not in most MSA-c patients., (© 2024 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)- Published
- 2024
- Full Text
- View/download PDF
6. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.
- Author
-
Van Weehaeghe D, Lapauw B, Fraioli F, Cecchin D, Verger A, Guedj E, Albert NL, Brendel M, Yakushev I, Barthel H, Traub-Weidinger T, Tolboom N, and Giessen EV
- Subjects
- Humans, Nuclear Medicine, Societies, Medical, Neuroendocrine Tumors diagnostic imaging, Pituitary Neoplasms diagnostic imaging, Positron-Emission Tomography
- Published
- 2024
- Full Text
- View/download PDF
7. Neuroimaging biomarkers in the biological definition of Parkinson's disease and dementia with Lewy bodies - EANM position on current state, unmet needs and future perspectives.
- Author
-
Brendel M, Guedj E, Yakushev I, Morbelli S, Höglinger GU, Tolboom N, Verger A, Albert NL, Cecchin D, Fernandez PA, Fraioli F, Traub-Weidinger T, Van Weehaeghe D, and Barthel H
- Published
- 2024
- Full Text
- View/download PDF
8. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.
- Author
-
Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, Guedj E, Furtner J, Fraioli F, Huang RY, Johnson DR, Deroose CM, Herrmann K, Vogelbaum M, Chang S, Tonn JC, Weller M, Wen PY, van den Bent MJ, Verger A, Ivanidze J, and Galldiks N
- Abstract
Purpose: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands., Methods: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO)., Results: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma., Conclusion: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. EANM perspectives for CZT SPECT in brain applications.
- Author
-
Verger A, Cecchin D, Guedj E, Albert NL, Brendel M, Fraioli F, Tolboom N, Traub-Weidinger T, Yakushev I, Van Weehaeghe D, Fernandez PA, Garibotto V, and Imbert L
- Published
- 2024
- Full Text
- View/download PDF
10. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy.
- Author
-
Traub-Weidinger T, Arbizu J, Barthel H, Boellaard R, Borgwardt L, Brendel M, Cecchin D, Chassoux F, Fraioli F, Garibotto V, Guedj E, Hammers A, Law I, Morbelli S, Tolboom N, Van Weehaeghe D, Verger A, Van Paesschen W, von Oertzen TJ, Zucchetta P, and Semah F
- Subjects
- Humans, Nuclear Medicine, Europe, Epilepsy diagnostic imaging, Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography methods, Positron-Emission Tomography standards
- Abstract
Epilepsy is one of the most frequent neurological conditions with an estimated prevalence of more than 50 million people worldwide and an annual incidence of two million. Although pharmacotherapy with anti-seizure medication (ASM) is the treatment of choice, ~30% of patients with epilepsy do not respond to ASM and become drug resistant. Focal epilepsy is the most frequent form of epilepsy. In patients with drug-resistant focal epilepsy, epilepsy surgery is a treatment option depending on the localisation of the seizure focus for seizure relief or seizure freedom with consecutive improvement in quality of life. Beside examinations such as scalp video/electroencephalography (EEG) telemetry, structural, and functional magnetic resonance imaging (MRI), which are primary standard tools for the diagnostic work-up and therapy management of epilepsy patients, molecular neuroimaging using different radiopharmaceuticals with single-photon emission computed tomography (SPECT) and positron emission tomography (PET) influences and impacts on therapy decisions. To date, there are no literature-based praxis recommendations for the use of Nuclear Medicine (NM) imaging procedures in epilepsy. The aims of these guidelines are to assist in understanding the role and challenges of radiotracer imaging for epilepsy; to provide practical information for performing different molecular imaging procedures for epilepsy; and to provide an algorithm for selecting the most appropriate imaging procedures in specific clinical situations based on current literature. These guidelines are written and authorized by the European Association of Nuclear Medicine (EANM) to promote optimal epilepsy imaging, especially in the presurgical setting in children, adolescents, and adults with focal epilepsy. They will assist NM healthcare professionals and also specialists such as Neurologists, Neurophysiologists, Neurosurgeons, Psychiatrists, Psychologists, and others involved in epilepsy management in the detection and interpretation of epileptic seizure onset zone (SOZ) for further treatment decision. The information provided should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals and imaging modalities., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
11. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.
- Author
-
Graillon T, Salgues B, Horowitz T, Padovani L, Appay R, Tabouret E, Guedj E, and Chinot O
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Aged, Adult, Magnetic Resonance Imaging, Follow-Up Studies, Peptides therapeutic use, Meningioma radiotherapy, Meningioma pathology, Meningioma diagnostic imaging, Meningeal Neoplasms radiotherapy, Meningeal Neoplasms pathology, Meningeal Neoplasms diagnostic imaging, Neoplasm Recurrence, Local radiotherapy
- Abstract
Purpose: Several retrospective studies and meta-analyses of Peptide Radionuclide Radiation Therapy in meningiomas suggest six-month progression-free survival improvement for WHO grade 1 and 2 meningiomas. In the present study, we aimed to evaluate the impact of such treatment on three-dimensional volume growth rate (3DVGR) in nonanaplastic meningiomas., Methods: The authors performed a retrospective study including eight patients treated with Lutathera®. Millimetric 3D T1-weighted with gadolinium enhancement magnetic resonance imaging sequences were requested for volume measurement. Then, tumor growth rate was classified following a previously described 3DVGR classification (Graillon et al.)., Results: Patients harbored seven WHO grade 2 meningiomas and one aggressive WHO grade 1. All patients, except one, underwent four treatment cycles. 3DVGR significantly decreased at 3, 6, and 12 months after treatment initiation analyzing each lesion separately. Mean and median 3DVGR from all patients were respectively at 29.5% and 44.5%/6 months before treatment initiation, then at 16.5% and 25%/6 months at three months post-treatment initiation, 9.5% and 4.5%/6 months after 6 months, as well as 9.5% and 10.5%/6 months after 12 months. At 3, 6, and 12 months after treatment initiation, 4/8, 6/7, and 5/6 patients were class 2 (stabilization or severe 3DVGR slowdown), respectively. No patient was class 1 at 6 and 12 months, suggesting a lack of drug response., Conclusion: In nonanaplastic meningiomas, Lutathera®'s antitumoral activity appeared delayed and more likely observed at six months, while no major response was observed under treatment. Moreover, its antitumoral activity persisted for 12-18 months following treatment initiation., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
12. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging.
- Author
-
Fraioli F, Albert N, Boellaard R, Galazzo IB, Brendel M, Buvat I, Castellaro M, Cecchin D, Fernandez PA, Guedj E, Hammers A, Kaplar Z, Morbelli S, Papp L, Shi K, Tolboom N, Traub-Weidinger T, Verger A, Van Weehaeghe D, Yakushev I, and Barthel H
- Subjects
- Humans, Radionuclide Imaging, Brain diagnostic imaging, Neuroimaging, Artificial Intelligence, Nuclear Medicine
- Published
- 2024
- Full Text
- View/download PDF
13. Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses.
- Author
-
Poussin C, Titz B, Xiang Y, Baglia L, Berg R, Bornand D, Choukrallah MA, Curran T, Dijon S, Dossin E, Dulize R, Etter D, Fatarova M, Medlin LF, Haiduc A, Kishazi E, Kolli AR, Kondylis A, Kottelat E, Laszlo C, Lavrynenko O, Eb-Levadoux Y, Nury C, Peric D, Rizza M, Schneider T, Guedj E, Calvino F, Sierro N, Guy P, Ivanov NV, Picavet P, Spinelli S, Hoeng J, and Peitsch MC
- Subjects
- Humans, Cross-Sectional Studies, Multiomics, Vaping, Smoking Cessation, Exposome, Tobacco Products, Electronic Nicotine Delivery Systems
- Abstract
Cigarette smoking is a major preventable cause of morbidity and mortality. While quitting smoking is the best option, switching from cigarettes to non-combustible alternatives (NCAs) such as e-vapor products is a viable harm reduction approach for smokers who would otherwise continue to smoke. A key challenge for the clinical assessment of NCAs is that self-reported product use can be unreliable, compromising the proper evaluation of their risk reduction potential. In this cross-sectional study of 205 healthy volunteers, we combined comprehensive exposure characterization with in-depth multi-omics profiling to compare effects across four study groups: cigarette smokers (CS), e-vapor users (EV), former smokers (FS), and never smokers (NS). Multi-omics analyses included metabolomics, transcriptomics, DNA methylomics, proteomics, and lipidomics. Comparison of the molecular effects between CS and NS recapitulated several previous observations, such as increased inflammatory markers in CS. Generally, FS and EV demonstrated intermediate molecular effects between the NS and CS groups. Stratification of the FS and EV by combustion exposure markers suggested that this position on the spectrum between CS and NS was partially driven by non-compliance/dual use. Overall, this study highlights the importance of in-depth exposure characterization before biological effect characterization for any NCA assessment study., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Theranostics in Neurooncology: Heading Toward New Horizons.
- Author
-
Tolboom N, Verger A, Albert NL, Fraioli F, Guedj E, Traub-Weidinger T, Morbelli S, Herrmann K, Zucchetta P, Plasschaert SLA, Yakushev I, Weller M, Glas M, Preusser M, Cecchin D, Barthel H, and Van Weehaeghe D
- Subjects
- Male, Child, Humans, Precision Medicine, Theranostic Nanomedicine methods, Blood-Brain Barrier, Brain Neoplasms diagnostic imaging, Brain Neoplasms therapy, Brain Neoplasms pathology, Glioma
- Abstract
Therapeutic approaches to brain tumors remain a challenge, with considerable limitations regarding delivery of drugs. There has been renewed and increasing interest in translating the popular theranostic approach well known from prostate and neuroendocrine cancer to neurooncology. Although far from perfect, some of these approaches show encouraging preliminary results, such as for meningioma and leptomeningeal spread of certain pediatric brain tumors. In brain metastases and gliomas, clinical results have failed to impress. Perspectives on these theranostic approaches regarding meningiomas, brain metastases, gliomas, and common pediatric brain tumors will be discussed. For each tumor entity, the general context, an overview of the literature, and future perspectives will be provided. Ongoing studies will be discussed in the supplemental materials. As most theranostic agents are unlikely to cross the blood-brain barrier, the delivery of these agents will be dependent on the successful development and clinical implementation of techniques enhancing permeability and retention. Moreover, the international community should strive toward sufficiently large and randomized studies to generate high-level evidence on theranostic approaches with radioligand therapies for central nervous system tumors., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
- Published
- 2024
- Full Text
- View/download PDF
15. Virtual Exercise in Medicine: A Proof of Concept in a Healthy Population.
- Author
-
Le Roy B, Martin-Krumm C, Poupon C, Richieri R, Malbos E, Barthélémy F, Guedj E, and Trousselard M
- Abstract
Background: Science is beginning to establish the benefits of the use of virtual reality (VR) in health care. This therapeutic approach may be an appropriate complementary treatment for some mental illnesses. It could prevent high levels of morbidity and improve the physical health of patients. For many years, the literature has shown the health benefits of physical exercise. Physical exercise in a VR environment may improve the management of mild to moderate mental health conditions. In this context, we developed a virtual environment combined with an ergocycle (the augmented physical training for isolated and confined environments [APTICE] system)., Objective: This study aims to investigate the impact of physical exercise in a VR environment., Methods: A total of 14 healthy participants (11 men and 3 women; mean age 43.28, SD 10.60 years) undertook 15 minutes of immersive physical exercise using the system. Measures included mindfulness and immersion disposition, subjective perceptions of sensory information, user experience, and VR experience (ie, psychological state, flow, and presence)., Results: First, the APTICE system appears to be a useful tool because the user experience is positive (subscales in the AttrakDiff questionnaire: pragmatic quality=0.99; hedonic quality-stimulation=1.90; hedonic quality-identification=0.67; attractiveness=1.58). Second, the system can induce a positive psychological state (negative emotion, P=.06) and an experience of flow and presence (P values ranging from <.001 to .04). Third, individual immersive and mindful disposition plays a role in the VR experience (P values ranging from <.02 to .04). Finally, our findings suggest that there is a link between the subjective perception of sensory information and the VR experience (P values ranging from <.02 to .04)., Conclusions: These results indicate that the device is well accepted with positive psychological and exteroceptive outcomes. Overall, the APTICE system could be a proof of concept to explore the benefits of virtual physical exercise in clinical medicine., (©Barbara Le Roy, Charles Martin-Krumm, Charlotte Poupon, Raphaëlle Richieri, Eric Malbos, Fanny Barthélémy, Eric Guedj, Marion Trousselard. Originally published in JMIR Formative Research (https://formative.jmir.org), 22.01.2024.)
- Published
- 2024
- Full Text
- View/download PDF
16. EANM position paper: theranostics in brain tumours-the present and the future.
- Author
-
Tolboom N, Verger A, Albert NL, Brendel M, Cecchin D, Fernandez PA, Fraioli F, Guedj E, Herrmann K, Traub-Weidinger T, Morbelli S, Yakushev I, Zucchetta P, Barthel H, and Van Weehaeghe D
- Subjects
- Humans, Precision Medicine, Positron-Emission Tomography, Nuclear Medicine, Brain Neoplasms diagnostic imaging, Brain Neoplasms radiotherapy
- Published
- 2023
- Full Text
- View/download PDF
17. Characterisation of a novel [ 18 F]FDG brain PET database and combination with a second database for optimising detection of focal abnormalities, using focal cortical dysplasia as an example.
- Author
-
Jin SO, Mérida I, Stavropoulos I, Elwes RDC, Lam T, Guedj E, Girard N, Costes N, and Hammers A
- Abstract
Background: Brain [
18 F]FDG PET is used clinically mainly in the presurgical evaluation for epilepsy surgery and in the differential diagnosis of neurodegenerative disorders. While scans are usually interpreted visually on an individual basis, comparison against normative cohorts allows statistical assessment of abnormalities and potentially higher sensitivity for detecting abnormalities. Little work has been done on out-of-sample databases (acquired differently to the patient data). Combination of different databases would potentially allow better power and discrimination. We fully characterised an unpublished healthy control brain [18 F]FDG PET database (Marseille, n = 60, ages 21-78 years) and compared it to another publicly available database (MRXFDG, n = 37, ages 23-65 years). We measured and then harmonised spatial resolution and global values. A collection of patient scans (n = 34, 13-48 years) with histologically confirmed focal cortical dysplasias (FCDs) obtained on three generations of scanners was used to estimate abnormality detection rates using standard software (statistical parametric mapping, SPM12)., Results: Regional SUVs showed similar patterns, but global values and resolutions were different as expected. Detection rates for the FCDs were 50% for comparison with the Marseille database and 53% for MRXFDG. Simply combining both databases worsened the detection rate to 41%. After harmonisation of spatial resolution, using a full factorial design matrix to accommodate global differences, and leaving out controls older than 60 years, we achieved detection rates of up to 71% for both databases combined. Detection rates were similar across the three scanner types used for patients, and high for patients whose MRI had been normal (n = 10/11)., Conclusions: As expected, global and regional data characteristics are database specific. However, our work shows the value of increasing database size and suggests ways in which database differences can be overcome. This may inform analysis via traditional statistics or machine learning, and clinical implementation., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
18. Brain FDG-PET correlates of saccadic disorders in early PSP.
- Author
-
Pin G, Labouré J, Guedj E, Felician O, Grimaldi S, Azulay JP, Ceccaldi M, and Koric L
- Subjects
- Humans, Retrospective Studies, Saccades, Brain, Positron-Emission Tomography methods, Fluorodeoxyglucose F18 metabolism, Supranuclear Palsy, Progressive diagnosis
- Abstract
Background: New diagnostic criteria of Progressive Supranuclear Palsy (PSP) have highlighted the interest of Eye Movement Records (EMR) at the early stage of the disease., Objectives: To investigate the metabolic brain correlates of ocular motor dysfunction using [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in early PSP., Methods: Retrospective observational descriptive study on longitudinal data with patients who underwent EMR and FDG-PET at the stage of suggestive and possible PSP according to Movement Disorders Society criteria. Longitudinal follow-up enables to confirm diagnosis of probable PSP. Using the Statistical Parametric Mapping software, we performed whole-brain voxel-based correlations between oculomotor variables and FDG-PET metabolism., Results: Thirty-seven patients with early PSP who fulfilled criteria of probable PSP during the follow-up were included. Decrease in the gain of vertical saccades correlated with reduced metabolism in Superior Colliculi (SC). We also found a positive correlation between mean velocity of horizontal saccades and SC metabolism as well as dorsal nuclei in the pons. Finally, increase in horizontal saccades latencies correlated with decrease of posterior parietal metabolism., Conclusions: These findings suggest the early involvement of SC in saccadic dysfunction in the course of PSP., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2023
- Full Text
- View/download PDF
19. Nicotine-mediated effects in neuronal and mouse models of synucleinopathy.
- Author
-
Fares MB, Alijevic O, Johne S, Overk C, Hashimoto M, Kondylis A, Adame A, Dulize R, Peric D, Nury C, Battey J, Guedj E, Sierro N, Mc Hugh D, Rockenstein E, Kim C, Rissman RA, Hoeng J, Peitsch MC, Masliah E, and Mathis C
- Abstract
Introduction: Alpha-synuclein (α-Syn) aggregation, transmission, and contribution to neurotoxicity represent central mechanisms underlying Parkinson's disease. The plant alkaloid "nicotine" was reported to attenuate α-Syn aggregation in different models, but its precise mode of action remains unclear., Methods: In this study, we investigated the effect of 2-week chronic nicotine treatment on α-Syn aggregation, neuroinflammation, neurodegeneration, and motor deficits in D-line α-Syn transgenic mice. We also established a novel humanized neuronal model of α-Syn aggregation and toxicity based on treatment of dopaminergic neurons derived from human induced pluripotent stem cells (iPSC) with α-Syn preformed fibrils (PFF) and applied this model to investigate the effects of nicotine and other compounds and their modes of action., Results and Discussion: Overall, our results showed that nicotine attenuated α-Syn-provoked neuropathology in both models. Moreover, when investigating the role of nicotinic acetylcholine receptor (nAChR) signaling in nicotine's neuroprotective effects in iPSC-derived dopaminergic neurons, we observed that while α4-specific antagonists reduced the nicotine-induced calcium response, α4 agonists (e.g., AZD1446 and anatabine) mediated similar neuroprotective responses against α-Syn PFF-provoked neurodegeneration. Our results show that nicotine attenuates α-Syn-provoked neuropathology in vivo and in a humanized neuronal model of synucleinopathy and that activation of α4β2 nicotinic receptors might mediate these neuroprotective effects., Competing Interests: OA, SJ, AK, RD, DP, CN, JB, EG, NS, DM, and CM are employees of Philip Morris International. MP was a PMI employee at the time of the study and is now retired. JH was a PMI employee at the time of the study and is now an employee of Vectura Fertin Pharma. MF was a PMI employee at the time of the study and is now a co-founder and director of R&D at ND Biosciences, a company developing next-generation therapeutics and diagnostics for neurodegenerative diseases. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Fares, Alijevic, Johne, Overk, Hashimoto, Kondylis, Adame, Dulize, Peric, Nury, Battey, Guedj, Sierro, Mc Hugh, Rockenstein, Kim, Rissman, Hoeng, Peitsch, Masliah and Mathis.)
- Published
- 2023
- Full Text
- View/download PDF
20. Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with 68 Ga-DOTATOC PET/CT.
- Author
-
Horowitz T, Salgues B, Padovani L, Farah K, Dufour H, Chinot O, Guedj E, and Graillon T
- Abstract
68 Ga-DOTATOC PET could be a noninvasive, highly sensitive, and specific technique for the challenging diagnosis of optic nerve sheath meningioma (ONSM). Our objective was to report the use and results of68 Ga-DOTATOC PET in suspected ONSM. Twelve subjects who underwent68 Ga-DOTATOC PET for suspected ONSM in our department were retrospectively included. Standardised clinical and radiological data were collected. The PET examination results were classified as positive or negative, and lesion standardised uptake values (SUVmax ) were recorded.68 Ga-DOTATOC PET confirmed positive uptake in six cases (SUVmax > 5), leading to ONSM diagnoses followed by radiation therapy in patients with vision loss. Six68 Ga-DOTATOC PET scans were considered negative (SUVmax < 5); these comprised one case of neurosarcoidosis, one cavernous malformation, and four uncertain diagnoses, leading to further investigation.68 Ga-DOTATOC PET was helpful in tumour volume delineation before radiation therapy, leading to a decrease in dose exposure. Noninvasive68 Ga-DOTATOC PET should be performed before treating nonhistologically proven meningiomas with radiotherapy or stereotactic radiosurgery, particularly in cases of uncertain diagnosis with MRI, which characterises most ONSM cases. PET SUVmax thresholds to distinguish meningioma from nonspecific uptake in other lesions need to be adapted to ONSM.68 Ga-DOTATOC PET improves the intraorbital lesion diagnostic approach and therefore impacts therapeutic management.- Published
- 2023
- Full Text
- View/download PDF
21. Metabolic patterns in brain 18F-fluorodeoxyglucose PET relate to aetiology in paediatric dystonia.
- Author
-
Tsagkaris S, Yau EKC, McClelland V, Papandreou A, Siddiqui A, Lumsden DE, Kaminska M, Guedj E, Hammers A, and Lin JP
- Subjects
- Adult, Infant, Newborn, Humans, Child, Fluorodeoxyglucose F18 metabolism, Brain metabolism, Positron-Emission Tomography methods, Glucose metabolism, Molecular Chaperones metabolism, DNA-Binding Proteins metabolism, Apoptosis Regulatory Proteins metabolism, Dystonia metabolism, Kernicterus complications, Kernicterus metabolism, Dystonic Disorders metabolism, Cerebral Palsy
- Abstract
There is a lack of imaging markers revealing the functional characteristics of different brain regions in paediatric dystonia. In this observational study, we assessed the utility of [18F]2-fluoro-2-deoxy-D-glucose (FDG)-PET in understanding dystonia pathophysiology by revealing specific resting awake brain glucose metabolism patterns in different childhood dystonia subgroups. PET scans from 267 children with dystonia being evaluated for possible deep brain stimulation surgery between September 2007 and February 2018 at Evelina London Children's Hospital (ELCH), UK, were examined. Scans without gross anatomical abnormality (e.g. large cysts, significant ventriculomegaly; n = 240) were analysed with Statistical Parametric Mapping (SPM12). Glucose metabolism patterns were examined in the 144/240 (60%) cases with the 10 commonest childhood-onset dystonias, focusing on nine anatomical regions. A group of 39 adult controls was used for comparisons. The genetic dystonias were associated with the following genes: TOR1A, THAP1, SGCE, KMT2B, HPRT1 (Lesch Nyhan disease), PANK2 and GCDH (Glutaric Aciduria type 1). The acquired cerebral palsy (CP) cases were divided into those related to prematurity (CP-Preterm), neonatal jaundice/kernicterus (CP-Kernicterus) and hypoxic-ischaemic encephalopathy (CP-Term). Each dystonia subgroup had distinct patterns of altered FDG-PET uptake. Focal glucose hypometabolism of the pallidi, putamina or both, was the commonest finding, except in PANK2, where basal ganglia metabolism appeared normal. HPRT1 uniquely showed glucose hypometabolism across all nine cerebral regions. Temporal lobe glucose hypometabolism was found in KMT2B, HPRT1 and CP-Kernicterus. Frontal lobe hypometabolism was found in SGCE, HPRT1 and PANK2. Thalamic and brainstem hypometabolism were seen only in HPRT1, CP-Preterm and CP-term dystonia cases. The combination of frontal and parietal lobe hypermetabolism was uniquely found in CP-term cases. PANK2 cases showed a distinct combination of parietal hypermetabolism with cerebellar hypometabolism but intact putaminal-pallidal glucose metabolism. HPRT1, PANK2, CP-kernicterus and CP-preterm cases had cerebellar and insula glucose hypometabolism as well as parietal glucose hypermetabolism. The study findings offer insights into the pathophysiology of dystonia and support the network theory for dystonia pathogenesis. 'Signature' patterns for each dystonia subgroup could be a useful biomarker to guide differential diagnosis and inform personalized management strategies., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.)
- Published
- 2023
- Full Text
- View/download PDF
22. Innovative treatments for meningiomas.
- Author
-
Graillon T, Tabouret E, Salgues B, Horowitz T, Padovani L, Appay R, Farah K, Dufour H, Régis J, Guedj E, Barlier A, and Chinot O
- Subjects
- Humans, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Proto-Oncogene Proteins c-akt therapeutic use, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases therapeutic use, Neoplasm Recurrence, Local, Mutation, Meningioma genetics, Meningioma therapy, Meningioma metabolism, Meningeal Neoplasms genetics, Meningeal Neoplasms therapy, Meningeal Neoplasms metabolism
- Abstract
Multi-recurrent high-grade meningiomas remain an unmet medical need in neuro-oncology when iterative surgeries and radiation therapy sessions fail to control tumor growth. Nevertheless, the last 10years have been marked by multiple advances in the comprehension of meningioma tumorigenesis via the discovery of new driver mutations, the identification of activated intracellular signaling pathways, and DNA methylation analyses, providing multiple potential therapeutic targets. Today, Anti-VEGF and mTOR inhibitors are the most used and probably the most active drugs in aggressive meningiomas. Peptide radioactive radiation therapy aims to target SSTR2A receptors, which are strongly expressed in meningiomas, but have an insufficient effect in most aggressive meningiomas, requiring the development of new techniques to increase the dose applied to the tumor. Based on the multiple potential intracellular targets, multiple targeted therapy clinical trials targeting Pi3K-Akt-mTOR and MAP kinase pathways as well as cell cycle and particularly, cyclin D4-6 are ongoing. Recently discovered driver mutations, SMO, Akt, and PI3KCA, offer new targets but are mostly observed in benign meningiomas, limiting their clinical relevance mainly to rare aggressive skull base meningiomas. Therefore, NF2 mutation remains the most frequent mutation and main challenging target in high-grade meningioma. Recently, inhibitors of focal adhesion kinase (FAK), which is involved in tumor cell adhesion, were tested in a phase 2 clinical trial with interesting but insufficient activity. The Hippo pathway was demonstrated to interact with NF2/Merlin and could be a promising target in NF2-mutated meningiomas with ongoing multiple preclinical studies and a phase 1 clinical trial. Recent advances in immune landscape comprehension led to the proposal of the use of immunotherapy in meningiomas. Except in rare cases of MSH2/6 mutation or high tumor mass burden, the activity of PD-1 inhibitors remains limited; however, its combination with various radiation therapy modalities is particularly promising. On the whole, therapeutic management of high-grade meningiomas is still challenging even with multiple promising therapeutic targets and innovations., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours.
- Author
-
Horowitz T, Tabouret E, Graillon T, Salgues B, Chinot O, Verger A, and Guedj E
- Subjects
- Humans, Fluorodeoxyglucose F18, Neoplasm Recurrence, Local, Positron-Emission Tomography methods, Amino Acids, Radiopharmaceuticals, Nuclear Medicine, Meningioma diagnostic imaging, Meningioma therapy, Glioma diagnostic imaging, Glioma therapy, Brain Neoplasms diagnostic imaging, Brain Neoplasms therapy, Meningeal Neoplasms, Lymphoma
- Abstract
Positron emission tomography (PET) is a powerful tool that can help physicians manage primary brain tumours at diagnosis and follow-up. In this context, PET imaging is used with three main types of radiotracers:
18 F-FDG, amino acid radiotracers, and68 Ga conjugated to somatostatin receptor ligands (SSTRs). At initial diagnosis,18 F-FDG helps to characterize primary central nervous system (PCNS) lymphomas and high-grade gliomas, amino acid radiotracers are indicated for gliomas, and SSTR PET ligands are indicated for meningiomas. Such radiotracers provide information on tumour grade or type, assist in directing biopsies and help with treatment planning. During follow-up, in the presence of symptoms and/or MRI modifications, the differential diagnosis between tumour recurrence and post-therapeutic changes, in particular radiation necrosis, may be challenging, and there is strong interest in using PET to evaluate therapeutic toxicity. PET may also contribute to identifying specific complications, such as postradiation therapy encephalopathy, encephalitis associated with PCNS lymphoma, and stroke-like migraine after radiation therapy (SMART) syndrome associated with glioma recurrence and temporal epilepsy, originally illustrated in this review. This review summarizes the main contribution of PET to the diagnosis, management, and follow-up of brain tumours, specifically gliomas, meningiomas, and primary central nervous system lymphomas., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
24. Regional brain glucose metabolism is differentially affected by ketogenic diet: a human semiquantitative positron emission tomography.
- Author
-
Horowitz T, Doche E, Philip M, Cammilleri S, Suissa L, and Guedj E
- Subjects
- Humans, Middle Aged, Aged, Adult, Fluorodeoxyglucose F18 metabolism, Retrospective Studies, Positron-Emission Tomography methods, Brain diagnostic imaging, Brain metabolism, Glucose metabolism, Diet, Ketogenic
- Abstract
Purpose: Ketogenic diet (KD) is recommended to avoid intense [
18 F]FDG myocardial physiologic uptake in PET imaging. Neuroprotective and anti-seizure effects of KD have been suggested, but their mechanisms remain to be elucidated. This [18 F]FDG PET study aims to evaluate the effect of KD on glucose brain metabolism., Method: Subjects who underwent KD prior to whole-body and brain [18 F]FDG PET between January 2019 and December 2020 in our department for suspected endocarditis were retrospectively included. Myocardial glucose suppression (MGS) on whole-body PET was analyzed. Patients with brain abnormalities were excluded. Thirty-four subjects with MGS (mean age: 61.8 ± 17.2 years) were included in the KD population, and 14 subjects without MGS were considered for a partial KD group (mean age: 62.3 ± 15.1 years). Brain SUVmax was first compared between these two KD groups to determine possible global uptake difference. Semiquantitative voxel-based intergroup analyses were secondarily performed to determine possible inter-regional differences by comparing KD groups with and without MGS, separately, to 27 healthy subjects fasting for at least 6 h (mean age of 62.4 ± 10.9 years), and KD groups between them (p-voxel < 0.001, and p-cluster < 0.05, FWE-corrected)., Results: A 20% lower brain SUVmax was found in subjects under KD with MGS in comparison to those without MGS (Student's t-test, p = 0.02). Whole-brain voxel-based intergroup analysis revealed that patients under KD with and without MGS had relative hypermetabolism of limbic regions including medial temporal cortices and cerebellum lobes and relative hypometabolism of bilateral posterior regions (occipital), without significant difference between them., Conclusion: KD globally reduces brain glucose metabolism but with regional differences, requiring special attention to clinical interpretation. On a pathophysiological perspective, these findings could help understand underlying neurological effects of KD through possible decrease of oxidative stress in posterior regions and functional compensation in the limbic regions., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
25. COVID19-associated new-onset movement disorders: a follow-up study.
- Author
-
Schneider SA, Desai S, Phokaewvarangkul O, Rosca EC, Sringean J, Anand P, Bravo GÁ, Cardoso F, Cervantes-Arslanian AM, Chovatiya H, Crosiers D, Dijkstra F, Fearon C, Grandas F, Guedj E, Méndez-Guerrero A, Hassan M, Jankovic J, Lang AE, Makhoul K, Muccioli L, O'Shea SA, Ostovan VR, Perez-Sanchez JR, Ramdhani R, Ros-Castelló V, Schulte C, Shah P, Wojtecki L, and Pal PK
- Subjects
- Male, Female, Humans, Aged, Follow-Up Studies, Risk Factors, Tremor complications, COVID-19 complications, Movement Disorders etiology
- Abstract
Background: Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited., Methods: Cases with new-onset COVID-19-associated movement disorders were identified by searching the literature. Authors were contacted for outcome data which were reviewed and analyzed., Results: Movement disorders began 12.6 days on average after the initial onset of COVID-19. 92% of patients required hospital admission (mean duration 23 days). In a fraction of patients (6 of 27; 22%; 4 males/2 females, mean age 66.8 years) the movement disorder (ataxia, myoclonus, tremor, parkinsonism) was still present after a follow-up period of 7.5 ± 3 weeks. Severe COVID-19 in general and development of encephalopathy were risk factors, albeit not strong predictors, for the persistence., Conclusions: The prognosis of new-onset COVID-19-associated movement disorder appears to be generally good. The majority recovered without residual symptoms within several weeks or months. Permanent cases may be due to unmasking of a previous subclinical movement disorder or due to vascular/demyelinating damage. Given the relatively low response rate of one third only and the heterogeneity of mechanisms firm conclusions on the (long-term) outome cannot, however, be drawn., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
26. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective.
- Author
-
Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, Fernandez PA, Fraioli F, Guedj E, Morbelli S, Tolboom N, Traub-Weidinger T, Van Weehaeghe D, and Barthel H
- Subjects
- Humans, Positron-Emission Tomography, Amyloid, Amyloid beta-Peptides, Neuroimaging, Alzheimer Disease diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
27. Tobacco Alkaloid Assessment in a DSS-Induced Colitis Mouse Model with a Fully Humanized Immune System.
- Author
-
Verhaeghe C, Talikka M, Sewer A, Sierro N, Auberson M, Peric D, Bornand D, Dulize R, Guedj E, Nef P, Tabruyn SP, Hoeng J, Peitsch MC, and Lo Sasso G
- Subjects
- Animals, Mice, Nicotiana adverse effects, Nicotine adverse effects, Disease Models, Animal, Anti-Inflammatory Agents therapeutic use, Immune System metabolism, Dextran Sulfate toxicity, Mice, Inbred C57BL, Colon metabolism, Colitis chemically induced, Colitis drug therapy, Colitis, Ulcerative chemically induced, Colitis, Ulcerative drug therapy, Colitis, Ulcerative metabolism, Inflammatory Bowel Diseases metabolism, Antineoplastic Agents therapeutic use, Alkaloids pharmacology, Alkaloids metabolism
- Abstract
Inflammatory bowel disease (IBD) refers to chronic intestinal immune-mediated diseases including two main disease manifestations: ulcerative colitis (UC) and Crohn's disease (CD). Epidemiological, clinical, and preclinical evidence has highlighted the potential anti-inflammatory properties of naturally occurring alkaloids. In the present study, we investigated the potential anti-inflammatory activities of the tobacco alkaloids nicotine and anatabine in a dextran sulfate sodium (DSS)-induced UC mouse model with a fully humanized immune system. Our results show that nicotine significantly reduced all acute colitis symptoms and improved colitis-specific endpoints, including histopathologically assessed colon inflammation, tissue damage, and mononuclear cell infiltration. The tobacco alkaloid anatabine showed similar effectiveness trends, although they were generally weaker or not significant. Gene expression analysis in the context of biological network models of IBD further pinpointed a possible mechanism by which nicotine attenuated DSS-induced colitis in humanized mice. The current study enables further investigation of possible molecular mechanisms by which tobacco alkaloids attenuate UC symptoms.
- Published
- 2023
- Full Text
- View/download PDF
28. Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up.
- Author
-
Saracino D, Sellami L, Boniface H, Houot M, Pélégrini-Issac M, Funkiewiez A, Rinaldi D, Locatelli M, Azuar C, Causse-Lemercier V, Jaillard A, Pasquier F, Chastan M, Wallon D, Hitzel A, Pariente J, Pallardy A, Boutoleau-Bretonnière C, Guedj E, Didic M, Migliaccio R, Kas A, Habert MO, and Le Ber I
- Subjects
- Humans, Follow-Up Studies, Progranulins genetics, Fluorodeoxyglucose F18, Prospective Studies, Cross-Sectional Studies, Mutation, Brain diagnostic imaging, Magnetic Resonance Imaging methods, Metabolome, Frontotemporal Dementia genetics
- Abstract
Background and Objectives: GRN variants are a frequent cause of familial frontotemporal dementia (FTD). Monitoring disease progression in asymptomatic carriers of genetic variants is a major challenge in delivering preventative therapies before clinical onset. This study aimed to assess the usefulness of fluorodeoxyglucose (FDG)-PET in identifying metabolic changes in presymptomatic GRN carriers (PS- GRN +) and to trace their longitudinal progression., Methods: Participants were longitudinally evaluated over 5 years in a prospective cohort study focused on GRN disease (Predict-PGRN). They underwent cognitive/behavioral assessment, plasma neurofilament measurement, brain MRI, and FDG-PET. Voxel-wise comparisons of structural and metabolic imaging data between 2 groups were performed for each time point. Longitudinal PET changes were evaluated with voxel-wise comparisons and the metabolic percent annual changes method. The association of regional brain metabolism with plasma neurofilament and cognitive changes was analyzed., Results: Among the 80 individuals enrolled in the study, 58 (27 PS- GRN + and 31 noncarriers) were included in the analyses. Cross-sectional comparisons between PS- GRN + and controls found a significant hypometabolism in the left superior temporal sulcus (STS) region (encompassing the middle and superior temporal gyri), approximately 15 years before the expected disease onset, without significant cortical atrophy. The longitudinal metabolic decline over the following 5 years peaked around the right STS in carriers ( p < 0.001), without significantly greater volume loss compared with that in controls. Their estimated annualized metabolic decrease (-1.37%) was higher than that in controls (-0.21%, p = 0.004). Lower glucose uptake was associated with higher neurofilament increase ( p = 0.003) and lower frontal cognitive scores ( p = 0.014) in PS- GRN +., Discussion: This study detected brain metabolic changes in the STS region, preceding structural and cognitive alterations, thus contributing to the characterization of the pathochronology of preclinical GRN disease. Owing to the STS involvement in the perception of facially communicated cues, it is likely that its dysfunction contributes to social cognition deficits characterizing FTD. Overall, our study highlights brain metabolic changes as an early disease-tracking biomarker and proposes annualized percent decrease as a metric to monitor therapeutic response in forthcoming trials., (© 2022 American Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
29. Correction to: [ 18 F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up.
- Author
-
Horowitz T, Kaphan E, and Guedj E
- Published
- 2022
- Full Text
- View/download PDF
30. [ 18 F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up.
- Author
-
Horowitz T, Kaphan E, and Guedj E
- Subjects
- Humans, Follow-Up Studies, Positron Emission Tomography Computed Tomography, Brain diagnostic imaging, Positron-Emission Tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals
- Published
- 2022
- Full Text
- View/download PDF
31. Systems biology reveals anatabine to be an NRF2 activator.
- Author
-
Messinis DE, Poussin C, Latino DARS, Eb-Levadoux Y, Dulize R, Peric D, Guedj E, Titz B, Ivanov NV, Peitsch MC, and Hoeng J
- Abstract
Anatabine, an alkaloid present in plants of the So lanaceae family (including tobacco and eggplant), has been shown to ameliorate chronic inflammatory conditions in mouse models, such as Alzheimer's disease, Hashimoto's thyroiditis, multiple sclerosis, and intestinal inflammation. However, the mechanisms of action of anatabine remain unclear. To understand the impact of anatabine on cellular systems and identify the molecular pathways that are perturbed, we designed a study to examine the concentration-dependent effects of anatabine on various cell types by using a systems pharmacology approach. The resulting dataset, consisting of measurements of various omics data types at different time points, was analyzed by using multiple computational techniques. To identify concentration-dependent activated pathways, we performed linear modeling followed by gene set enrichment. To predict the functional partners of anatabine and the involved pathways, we harnessed the LINCS L1000 dataset's wealth of information and implemented integer linear programming on directed graphs, respectively. Finally, we experimentally verified our key computational predictions. Using an appropriate luciferase reporter cell system, we were able to demonstrate that anatabine treatment results in NRF2 (nuclear factor-erythroid factor 2-related factor 2) translocation, and our systematic phosphoproteomic assays showed that anatabine treatment results in activation of MAPK signaling. While there are certain areas to be explored in deciphering the exact anti-inflammatory mechanisms of action of anatabine and other NRF2 activators, we believe that anatabine constitutes an interesting molecule for its therapeutic potential in NRF2-related diseases., Competing Interests: All authors are employees of Philip Morris International., (Copyright © 2022 Messinis, Poussin, Latino, Eb-Levadoux, Dulize, Peric, Guedj, Titz, Ivanov, Peitsch and Hoeng.)
- Published
- 2022
- Full Text
- View/download PDF
32. 2-[ 18 F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee.
- Author
-
Verger A, Barthel H, Tolboom N, Fraioli F, Cecchin D, Albert NL, van Berckel B, Boellaard R, Brendel M, Ekmekcioglu O, Semah F, Traub-Weidinger T, van de Weehaeghe D, Morbelli S, and Guedj E
- Subjects
- Brain diagnostic imaging, Humans, Neuroimaging, Positron-Emission Tomography methods, Radiopharmaceuticals, Post-Acute COVID-19 Syndrome, COVID-19 complications, Fluorodeoxyglucose F18
- Published
- 2022
- Full Text
- View/download PDF
33. Rasmussen's encephalitis: Early diagnostic criteria in children.
- Author
-
Villeneuve N, Lépine A, Girard N, Guedj E, and Daquin G
- Subjects
- Atrophy, Brain pathology, Child, Chronic Disease, Early Diagnosis, Electroencephalography, Humans, Magnetic Resonance Imaging, Encephalitis complications, Encephalitis diagnosis, Encephalitis therapy
- Abstract
Rasmussen's encephalitis (RE) is a rare chronic inflammatory brain disorder resulting in progressive neurodegeneration in one cerebral hemisphere. The inflammatory process is accompanied by progressive loss of function of the affected hemisphere, associated with drug-resistant partial epilepsy. The diagnosis is based on a range of clinical, electroencephalographic, radiological and biochemical arguments, without any specific formal marker, which makes the diagnosis of the disease complex, especially in its initial phase. Seizures are refractory to anti-seizures medication (ASM) and to classical immunomodulatory treatments. These treatments are also ineffective to stop the degenerative process. Only surgical treatment with hemispherotomy (surgical disconnection of a cerebral hemisphere) allows definitive cessation of seizures but this leads to definitive motor and cognitive deficits. The etiology of RE is not known, but there is strong evidence for an immunopathogenic mechanism involving T-cell mediated immunity. The emergence of biotherapies targeting against various cytokines offers potential therapeutic perspectives. This disease is currently a real challenge in terms of: (i) early diagnosis, before the constitution of marked hemispheric atrophy and the appearance of neurological and cognitive consequences; (ii) recognition of incomplete form; (iii) therapeutic management due to advances in the field of targeted treatment of inflammation; (iv) surgery and recovery possibilities., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Brain Metabolic PET Findings on the Long-Term Effects of COVID-19.
- Author
-
Guedj E and Horowitz T
- Subjects
- Brain diagnostic imaging, Brain metabolism, Fluorodeoxyglucose F18 metabolism, Humans, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals metabolism, COVID-19
- Published
- 2022
- Full Text
- View/download PDF
35. Diaphragm dysfunction after severe COVID-19: An ultrasound study.
- Author
-
Boussuges A, Habert P, Chaumet G, Rouibah R, Delorme L, Menard A, Million M, Bartoli A, Guedj E, Gouitaa M, Zieleskiewicz L, Finance J, Coiffard B, Delliaux S, and Brégeon F
- Abstract
Background: SARS-CoV-2 infection can impair diaphragm function at the acute phase but the frequency of diaphragm dysfunction after recovery from COVID-19 remains unknown., Materials and Methods: This study was carried out on patients reporting persistent respiratory symptoms 3-4 months after severe COVID-19 pneumonia. The included patients were selected from a medical consultation designed to screen for recovery after acute infection. Respiratory function was assessed by a pulmonary function test, and diaphragm function was studied by ultrasonography., Results: In total, 132 patients (85M, 47W) were recruited from the medical consultation. During the acute phase of the infection, the severity of the clinical status led to ICU admission for 58 patients (44%). Diaphragm dysfunction (DD) was detected by ultrasonography in 13 patients, two of whom suffered from hemidiaphragm paralysis. Patients with DD had more frequently muscle pain complaints and had a higher frequency of prior cardiothoracic or upper abdominal surgery than patients with normal diaphragm function. Pulmonary function testing revealed a significant decrease in lung volumes and DLCO and the dyspnea scores (mMRC and Borg10 scores) were significantly increased in patients with DD. Improvement in respiratory function was recorded in seven out of nine patients assessed 6 months after the first ultrasound examination., Conclusion: Assessment of diaphragm function by ultrasonography after severe COVID-19 pneumonia revealed signs of dysfunction in 10% of our population. In some cases, ultrasound examination probably discovered an un-recognized pre-existing DD. COVID-19 nonetheless contributed to impairment of diaphragm function. Prolonged respiratory physiotherapy led to improvement in respiratory function in most patients., Clinical Trial Registration: [www.cnil.fr], identifier [#PADS20-207]., Competing Interests: GC was employed by ALTRA BIO. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest., (Copyright © 2022 Boussuges, Habert, Chaumet, Rouibah, Delorme, Menard, Million, Bartoli, Guedj, Gouitaa, Zieleskiewicz, Finance, Coiffard, Delliaux and Brégeon.)
- Published
- 2022
- Full Text
- View/download PDF
36. Somatostatin Receptor Theranostics for Refractory Meningiomas.
- Author
-
Salgues B, Graillon T, Horowitz T, Chinot O, Padovani L, Taïeb D, and Guedj E
- Subjects
- Humans, Positron-Emission Tomography, Precision Medicine, Radionuclide Imaging, Receptors, Somatostatin, Retrospective Studies, Treatment Outcome, Yttrium Radioisotopes, Meningeal Neoplasms radiotherapy, Meningioma radiotherapy
- Abstract
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 177Lu-DOTATATE and an overall analysis of progression-free survival at 6 months (PFS-6) of the same relevant studies in the literature. Eight patients with recurrent and progressive WHO grade II meningiomas were treated after multimodal pretreatment with 177Lu-DOTATATE between 2019 and 2022. Primary and secondarily endpoints were progression-free survival at 6-months (PFS-6) and toxicity, respectively. PFS-6 analysis of our case series was compared with other similar relevant studies that included 86 patients treated with either 177Lu-DOTATATE or 90Y-DOTATOC. Our retrospective study showed a PFS-6 of 85.7% for WHO grade II progressive refractory meningiomas. Treatment was clinically and biologically well tolerated. The overall analysis of the previous relevant studies showed a PFS-6 of 89.7% for WHO grade I meningiomas ( n = 29); 57.1% for WHO grade II ( n = 21); and 0 % for WHO grade III ( n = 12). For all grades ( n = 86), including unknown grades, PFS-6 was 58.1%. SSTR-targeted PRRT allowed us to achieve prolonged PFS-6 in patients with WHO grade I and II progressive refractory meningiomas, except the most aggressive WHO grade II tumors. Large scale randomized trials are warranted for the better integration of PRRT in the treatment of refractory meningioma into clinical practice guidelines.
- Published
- 2022
- Full Text
- View/download PDF
37. Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience.
- Author
-
Verger A, Kas A, Dudouet P, Goehringer F, Salmon-Ceron D, and Guedj E
- Subjects
- Brain diagnostic imaging, Brain metabolism, Female, Humans, Middle Aged, Positron-Emission Tomography methods, Radiopharmaceuticals metabolism, Retrospective Studies, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications, COVID-19 diagnostic imaging, Fluorodeoxyglucose F18 metabolism
- Abstract
Background: This multicentre study aimed to provide a qualitative and consensual description of brain hypometabolism observed through the visual analysis of
18 F-FDG PET images of patients with suspected neurological long COVID, regarding the previously reported long-COVID hypometabolic pattern involving hypometabolism in the olfactory bulbs and other limbic/paralimbic regions, as well as in the brainstem and cerebellum., Methods: From the beginning of August 2021 to the end of October 2021, the brain18 F-FDG PET scans of patients referred for suspected neurological long COVID with positive reverse transcription polymerase chain reaction (RT-PCR) and/or serology tests for SARS-CoV-2 infection were retrospectively reviewed in three French nuclear medicine departments (143 patients; 47.4 years old ± 13.6; 98 women). Experienced nuclear physicians from each department classified brain18 F-FDG PET scans according to the same visual interpretation analysis as being normal, mildly to moderately (or incompletely) affected, or otherwise severely affected within the previously reported long-COVID hypometabolic pattern., Results: On the 143 brain18 F-FDG PET scans performed during this 3-month period, 53% of the scans were visually interpreted as normal, 21% as mildly to moderately or incompletely affected, and 26% as severely affected according to the COVID hypometabolic pattern. On average, PET scans were performed at 10.9 months from symptom onset (± 4.8). Importantly, this specific hypometabolic pattern was similarly identified in the three nuclear medicine departments. Typical illustrative examples are provided to help nuclear physicians interpret long-COVID profiles., Conclusion: The proposed PET metabolic pattern is easily identified upon visual interpretation in clinical routine for approximately one half of patients with suspected neurological long COVID, requiring special consideration for frontobasal paramedian regions, the brainstem and the cerebellum, and certainly further adapted follow-up and medical care, while the second half of patients have normal brain PET metabolism on average 10.9 months from symptom onset., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
38. Correlation between fluorodeoxyglucose positron emission tomography brain hypometabolism and posttraumatic stress disorder symptoms in temporal lobe epilepsy.
- Author
-
Soncin LD, Faure S, McGonigal A, Horowitz T, Belquaid S, Bartolomei F, and Guedj E
- Subjects
- Brain diagnostic imaging, Electroencephalography, Fluorodeoxyglucose F18, Humans, Magnetic Resonance Imaging, Positron-Emission Tomography methods, Epilepsy, Temporal Lobe complications, Epilepsy, Temporal Lobe diagnostic imaging, Stress Disorders, Post-Traumatic diagnostic imaging
- Abstract
The relationship between posttraumatic stress disorder (PTSD) and focal epilepsy is poorly understood. It has been hypothesized that there is a complex and reciprocal potential reinforcement of the symptoms of each condition. In this study, we investigated whether there are PTSD-specific brain changes in temporal lobe epilepsy (TLE). Brain fluorodeoxyglucose positron emission tomography (PET) metabolism was compared between controls and two groups of TLE patients: one group of 15 patients fulfilling the criteria for a potential diagnosis of PTSD (TLE-PTSD+), another group of 24 patients without a diagnosis of PTSD (TLE-PTSD-), and a group of 30 healthy control participants. We compared the differences in brain PET metabolism among these three groups, and we studied their correlations with interictal and peri-ictal scales of PTSD symptoms. TLE-PTSD+ patients showed more significant hypometabolism involving right temporal and right orbitofrontal cortex in comparison to TLE-PTSD- patients and healthy subjects. Moreover, degree of reduced metabolism in these brain areas correlated with interictal and peri-ictal PTSD questionnaire scores. PTSD in temporal epilepsy is associated with specific changes in neural networks, affecting limbic and paralimbic structures. This illustrates the close intertwining of epileptogenic and psychogenic processes in these patients., (© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)
- Published
- 2022
- Full Text
- View/download PDF
39. FDG-PET to T1 Weighted MRI Translation with 3D Elicit Generative Adversarial Network (E-GAN).
- Author
-
Bazangani F, Richard FJP, Ghattas B, and Guedj E
- Subjects
- Humans, Imaging, Three-Dimensional, Magnetic Resonance Imaging methods, Positron-Emission Tomography, Fluorodeoxyglucose F18, Image Processing, Computer-Assisted methods
- Abstract
Objective: With the strengths of deep learning, computer-aided diagnosis (CAD) is a hot topic for researchers in medical image analysis. One of the main requirements for training a deep learning model is providing enough data for the network. However, in medical images, due to the difficulties of data collection and data privacy, finding an appropriate dataset (balanced, enough samples, etc.) is quite a challenge. Although image synthesis could be beneficial to overcome this issue, synthesizing 3D images is a hard task. The main objective of this paper is to generate 3D T1 weighted MRI corresponding to FDG-PET. In this study, we propose a separable convolution-based Elicit generative adversarial network (E-GAN). The proposed architecture can reconstruct 3D T1 weighted MRI from 2D high-level features and geometrical information retrieved from a Sobel filter. Experimental results on the ADNI datasets for healthy subjects show that the proposed model improves the quality of images compared with the state of the art. In addition, the evaluation of E-GAN and the state of art methods gives a better result on the structural information (13.73% improvement for PSNR and 22.95% for SSIM compared to Pix2Pix GAN) and textural information (6.9% improvements for homogeneity error in Haralick features compared to Pix2Pix GAN).
- Published
- 2022
- Full Text
- View/download PDF
40. Molecular imaging in Parkinsonism: The essential for clinical practice and future perspectives.
- Author
-
Horowitz T, Grimaldi S, Azulay JP, and Guedj E
- Subjects
- Diagnosis, Differential, Humans, Molecular Imaging methods, Positron-Emission Tomography methods, Tomography, Emission-Computed, Single-Photon methods, Parkinson Disease diagnostic imaging, Parkinsonian Disorders diagnostic imaging
- Abstract
Nuclear medicine with positron emission tomography (PET) and single photon emission computed tomography (SPECT) develops powerful tools in molecular imaging to help clinicians in the challenging diagnosis of parkinsonism. These techniques can provide biomarkers for neurodegenerative parkinsonism and to distinguish Parkinson disease (PD) from atypical parkinsonism. This review summarizes the main SPECT and PET contributions to the diagnosis of parkinsonism. We will also discuss new technologies in the field of nuclear imaging and their potential contribution to the diagnosis of parkinsonian syndromes., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Correction to: EANM procedure guidelines for brain PET imaging using [ 18 F]FDG, version 3.
- Author
-
Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, and Morbelli S
- Published
- 2022
- Full Text
- View/download PDF
42. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
- Author
-
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Chételat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerström M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fröhlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, Gómez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lleó A, Löwenmark M, Madsen K, Maier W, Marcusson J, Marquié M, Martinez-Lage P, Maserejian N, Mattsson N, de Mendonça A, Meyer PT, Miller BL, Minatani S, Mintun MA, Mok VCT, Molinuevo JL, Morbelli SD, Morris JC, Mroczko B, Na DL, Newberg A, Nobili F, Nordberg A, Olde Rikkert MGM, de Oliveira CR, Olivieri P, Orellana A, Paraskevas G, Parchi P, Pardini M, Parnetti L, Peters O, Poirier J, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Reiman EM, Rinne JO, Rodrigue KM, Rodríguez-Rodriguez E, Roe CM, Rosa-Neto P, Rosen HJ, Rot U, Rowe CC, Rüther E, Ruiz A, Sabri O, Sakhardande J, Sánchez-Juan P, Sando SB, Santana I, Sarazin M, Scheltens P, Schröder J, Selnes P, Seo SW, Silva D, Skoog I, Snyder PJ, Soininen H, Sollberger M, Sperling RA, Spiru L, Stern Y, Stomrud E, Takeda A, Teichmann M, Teunissen CE, Thompson LI, Tomassen J, Tsolaki M, Vandenberghe R, Verbeek MM, Verhey FRJ, Villemagne V, Villeneuve S, Vogelgsang J, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Yen TC, Zboch M, and Zetterberg H
- Subjects
- Aged, Amyloid beta-Peptides cerebrospinal fluid, Amyloidogenic Proteins, Apolipoproteins E genetics, Biomarkers cerebrospinal fluid, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Peptide Fragments cerebrospinal fluid, Positron-Emission Tomography, Prevalence, tau Proteins cerebrospinal fluid, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease diagnostic imaging, Alzheimer Disease epidemiology, Amyloidosis, Cognitive Dysfunction diagnostic imaging, Cognitive Dysfunction epidemiology
- Abstract
Importance: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design., Objective: To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates., Design, Setting, and Participants: This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria., Exposures: Alzheimer disease biomarkers detected on PET or in CSF., Main Outcomes and Measures: Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations., Results: Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P = .04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P = .004), subjective cognitive decline (9%; 95% CI, 3%-15%; P = .005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P = .004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P = .18)., Conclusions and Relevance: This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.
- Published
- 2022
- Full Text
- View/download PDF
43. PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.
- Author
-
Verger A, Kas A, Darcourt J, and Guedj E
- Abstract
PET plays an increasingly important role in the management of brain tumors. This review outlines currently available PET radiotracers and their respective indications. It specifically focuses on
18 F-FDG, amino acid and somatostatin receptor radiotracers, for imaging gliomas, meningiomas, primary central nervous system lymphomas as well as brain metastases. Recent advances in radiopharmaceuticals, image analyses and translational applications to therapy are also discussed. The objective of this review is to provide a comprehensive overview of PET imaging's potential in neuro-oncology as an adjunct to brain MRI for all medical professionals implicated in brain tumor diagnosis and care.- Published
- 2022
- Full Text
- View/download PDF
44. Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia.
- Author
-
Fond G, Garosi A, Faugere M, Campion JY, Lancon C, Boyer L, Richieri R, and Guedj E
- Subjects
- Brain diagnostic imaging, Humans, Inflammation complications, Inflammation diagnostic imaging, Magnetic Resonance Imaging, Perfusion, Tomography, Emission-Computed, Single-Photon, Schizophrenia complications, Schizophrenia diagnostic imaging, Schizophrenia drug therapy
- Abstract
Purpose: Peripheral inflammation is frequent in schizophrenia and could play a role in the pathophysiology, prognosis, and persistence of psychotic symptomatology under treatment. We seek to determine the relationship between peripheral inflammation and brain SPECT perfusion in stabilized antipsychotic-treated outpatients with schizophrenia, and to determine whether such perfusion changes are correlated with persistent symptoms., Methods: Highly sensitive C-reactive protein blood level (hs-CRP) and brain SPECT perfusion were assessed in 137 stabilized outpatients with schizophrenia. Whole-brain voxel-based associations were searched with SPM between SPECT perfusion and hs-CRP (correlation analysis to quantitative levels and between-group analysis according to a threshold of 3 mg/L). The identified clusters were secondarily correlated with clinical symptoms., Results: After adjustment for age, sex, educational level, illness duration, antidepressant use, chlorpromazine equivalent dose, tobacco smoking and obesity, a negative correlation was found between hs-CRP level and the perfusion of 4 brain areas: the right inferior frontal gyrus, the right middle/superior temporal gyrus, the left superior parietal lobe, and the right postcentral/transverse temporal gyrus (p-voxel < 0.001, k > 80, uncorrected). Increased perfusion of the left amygdala was found in patients with hs-CRP ≥ 3 mg/L compared to those with hs-CRP levels < 3 mg/L. A negative correlation was found between perfusion of the right inferior frontal gyrus and the persistence of positive, negative, and excitement symptoms under antipsychotic treatment., Conclusion: In stabilized patients with schizophrenia, peripheral inflammation is associated with brain perfusion changes that are correlated with the persistence of psychotic symptomatology., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
45. Decrease in the cortex/striatum metabolic ratio on [ 18 F]-FDG PET: a biomarker of autoimmune encephalitis.
- Author
-
De Leiris N, Ruel B, Vervandier J, Boucraut J, Grimaldi S, Horowitz T, Pelletier J, Fluchere F, Campion JY, Kaphan E, and Guedj E
- Subjects
- Biomarkers, Humans, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiopharmaceuticals, Retrospective Studies, Encephalitis diagnostic imaging, Fluorodeoxyglucose F18
- Abstract
Purpose: The aim of this [
18 F]-FDG PET study was to determine the diagnostic value of the cortex/striatum metabolic ratio in a large cohort of patients suffering from autoimmune encephalitis (AE) and to search for correlations with the course of the disease., Methods: We retrospectively collected clinical and paraclinical data of patients with AE, including brain18 F-FDG PET/CT. Whole-brain statistical analysis was performed using SPM8 software after activity parametrization to the striatum in comparison to healthy subjects. The discriminative performance of this metabolic ratio was evaluated in patients with AE using receiver operating characteristic curves against 44 healthy subjects and a control group of 688 patients with MCI. Relationship between cortex/striatum metabolic ratios and clinical/paraclinical data was assessed using univariate and multivariate analysis in patients with AE., Results: Fifty-six patients with AE were included. In comparison to healthy subjects, voxel-based statistical analysis identified one large cluster (p-cluster < 0.05, FWE corrected) of widespread decreased cortex/striatum ratio in patients with AE. The mean metabolic ratio was significantly lower for AE patients (1.16 ± 0.13) than that for healthy subjects (1.39 ± 0.08; p < 0.001) and than that for MCI patients (1.32 ± 0.11; p < 0.001). A ratio threshold of 1.23 allowed to detect AE patients with a sensitivity of 71% and a specificity of 82% against MCI patients, and 98% against healthy subjects. A lower cortex/striatum metabolic ratio had a trend towards shorter delay before18 F-FDG PET/CT (p = 0.07) in multivariate analysis., Conclusion: The decrease in the cortex/striatal metabolic ratio has a good early diagnostic performance for the differentiation of AE patients from controls., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
46. Similar patterns of [ 18 F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series.
- Author
-
Morand A, Campion JY, Lepine A, Bosdure E, Luciani L, Cammilleri S, Chabrol B, and Guedj E
- Subjects
- Brain diagnostic imaging, Child, Fluorodeoxyglucose F18, Humans, Positron-Emission Tomography, Retrospective Studies, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications
- Abstract
Purpose: Several weeks after COVID-19 infection, some children report the persistence or recurrence of functional complaints. This clinical presentation has been referred as "long COVID" in the adult population, and an [
18 F]-FDG brain PET hypometabolic pattern has recently been suggested as a biomarker. Herein, we present a retrospective analysis of 7 paediatric patients with suspected long COVID who were explored by [18 F]-FDG brain PET exam. Metabolic brain findings were confronted to those obtained in adult patients with long COVID, in comparison to their respective age-matched control groups., Methods: Review of clinical examination and whole-brain voxel-based analysis of [18 F]-FDG PET metabolism of the 7 children in comparison to 21 paediatric controls, 35 adult patients with long COVID and 44 healthy adult subjects., Results: Despite lower initial severity at the acute stage of the infection, paediatric patients demonstrated on average 5 months later a similar brain hypometabolic pattern as that found in adult long COVID patients, involving bilateral medial temporal lobes, brainstem and cerebellum (p-voxel < 0.001, p-cluster < 0.05 FWE-corrected), and also the right olfactory gyrus after small volume correction (p-voxel = 0.010 FWE-corrected), with partial PET recovery in two children at follow-up., Conclusion: These results provide arguments in favour of possible long COVID in children, with a similar functional brain involvement to those found in adults, regardless of age and initial severity., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
47. The impact of COVID-19 lockdown on brain metabolism.
- Author
-
Guedj E, Campion JY, Horowitz T, Barthelemy F, Cammilleri S, and Ceccaldi M
- Subjects
- Aged, Aged, 80 and over, Brain diagnostic imaging, Emotions, Exercise, Female, Fluorodeoxyglucose F18, Humans, Longitudinal Studies, Male, Middle Aged, Motor Cortex diagnostic imaging, Motor Cortex metabolism, Nerve Net metabolism, Positron-Emission Tomography, Radiopharmaceuticals, Retrospective Studies, Social Isolation, Somatosensory Cortex diagnostic imaging, Somatosensory Cortex metabolism, Post-Acute COVID-19 Syndrome, Brain metabolism, COVID-19 complications, COVID-19 metabolism, Pandemics, Quarantine
- Abstract
This study aims to evaluate the impact of French national lockdown of 55 days on brain metabolism of patients with neurological disorders. Whole-brain voxel-based PET analysis was used to correlate
18 F-FDG metabolism to the number of days after March 17, 2020 (in 95 patients; mean age: 54.3 years ± 15.7; 59 men), in comparison to the same period in 2019 before the SARS-CoV-2 outbreak (in 212 patients; mean age: 59.5 years ± 15.8; 114 men), and to the first 55 days of deconfinement (in 188 patients; mean age: 57.5 years ± 16.5; 93 men). Lockdown duration was negatively correlated to the metabolism of the sensory-motor cortex with a prevailing effect on the left dominant pyramidal tract and on younger patients, also including the left amygdala, with only partial reversibility after 55 days of deconfinement. Weak overlap was found with the reported pattern of hypometabolism in long COVID (<9%). Restriction of physical activities, and possible related deconditioning, and social isolation may lead to functional disturbances of sensorimotor and emotional brain networks. Of note, this metabolic pattern seems distinct to those reported in long COVID. Further longitudinal studies with longer follow-up are needed to evaluate clinical consequences and relationships on cognitive and mental health against functional deactivation hypothesis, and to extend these findings to healthy subjects in the context of lockdown., (© 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.)- Published
- 2022
- Full Text
- View/download PDF
48. EANM procedure guidelines for brain PET imaging using [ 18 F]FDG, version 3.
- Author
-
Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, and Morbelli S
- Subjects
- Brain diagnostic imaging, Brain metabolism, Humans, Positron-Emission Tomography, Tomography, X-Ray Computed, Fluorodeoxyglucose F18 metabolism, Nuclear Medicine
- Abstract
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [
18 F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18 F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18 F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations., (© 2021. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
49. Metabolic connectivity is associated with seizure outcome in surgically treated temporal lobe epilepsies: A 18 F-FDG PET seed correlation analysis.
- Author
-
Doyen M, Chawki MB, Heyer S, Guedj E, Roch V, Marie PY, Tyvaert L, Maillard L, and Verger A
- Subjects
- Humans, Fluorodeoxyglucose F18 metabolism, Anterior Temporal Lobectomy, Seizures diagnostic imaging, Seizures etiology, Seizures surgery, Temporal Lobe diagnostic imaging, Temporal Lobe surgery, Temporal Lobe metabolism, Treatment Outcome, Magnetic Resonance Imaging, Epilepsy, Temporal Lobe diagnostic imaging, Epilepsy, Temporal Lobe surgery, Epilepsy, Temporal Lobe complications
- Abstract
18 F-FDG PET provides high sensitivity for the pre-surgical assessment of drug-resistant temporal lobe epilepsy (TLE). However, little is known about the metabolic connectivity of epileptogenic networks involved. This study therefore aimed to evaluate the association between metabolic connectivity and seizure outcome in surgically treated TLE., Methods: The study included 107 right-handed patients that had undergone a presurgical interictal18 F-FDG PET assessment followed by an anterior temporal lobectomy and were classified according to seizure outcome 2 years after surgery. Metabolic connectivity was evaluated by seed correlation analysis in left and right epilepsy patients with a Class Engel IA or > IA outcome and compared to age-, sex- and handedness-matched healthy controls., Results: Increased metabolic connectivity was observed in the >IA compared to the IA group within the operated temporal lobe (respective clusters of 7.5 vs 3.3 cm3 and 2.6 cm3 vs 2.2 cm3 in left and right TLE), and to a lower extent with the contralateral temporal lobe (1.2 vs 0.7 cm3 and 1.7 cm3 vs 0.7 cm3 in left and right TLE). Seed correlations provided added value for the estimated individual performance of seizure outcome over the group comparisons in left TLE (AUC of 0.74 vs 0.67)., Conclusion: Metabolic connectivity is associated with outcome in surgically treated TLE with a strengthened epileptogenic connectome in patients with non-free-seizure outcomes. The added value of seed correlation analysis in left TLE underlines the importance of evaluating metabolic connectivity in network related diseases., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
50. Aortic 18 F-FDG PET/CT hypermetabolism in patients with long COVID: a retrospective study.
- Author
-
Dudouet P, Cammilleri S, Guedj E, Jacquier A, Raoult D, and Eldin C
- Subjects
- Humans, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Retrospective Studies, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications, Fluorodeoxyglucose F18
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.